{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:45:09Z","timestamp":1787993109076,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Artif Organs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10047-024-01462-y","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T21:02:08Z","timestamp":1722632528000},"page":"216-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relation between antithrombin-III activity and activated clotting time for cardiopulmonary bypass"],"prefix":"10.1007","volume":"28","author":[{"given":"Tomoaki","family":"Yamashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-6233","authenticated-orcid":false,"given":"Yoshiyuki","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"1462_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1051\/ject\/201850005","volume":"50","author":"L Shore-Lesserson","year":"2018","unstructured":"Shore-Lesserson L, Baker RA, Ferraris V, Greilich PE, Fitzgerald D, Roman P, et al. STS\/SCA\/ AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass. J Extra Corpor Technol. 2018;50:5\u201318.","journal-title":"J Extra Corpor Technol"},{"key":"1462_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMra2104091","volume":"385","author":"JH Levy","year":"2021","unstructured":"Levy JH, Connors JM. Heparin resistance-clinical perspectives and management strategies. N Engl J Med. 2021;385:826\u201332.","journal-title":"N Engl J Med"},{"key":"1462_CR3","first-page":"297","volume":"9","author":"F Panicucci","year":"1980","unstructured":"Panicucci F, Sagripanti A, Conte B, Pinori E, Vispi M, Lecchini L. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Haemostasis. 1980;9:297\u2013302.","journal-title":"Haemostasis"},{"key":"1462_CR4","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.athoracsur.2018.01.068","volume":"105","author":"S Kawatsu","year":"2018","unstructured":"Kawatsu S, Sasaki K, Sakatsume K, Takahara S, Hosoyama K, Masaki N, et al. Predictors of heparin resistance before cardiovascular operations in adults. Ann Thorac Surg. 2018;105:1316\u201321.","journal-title":"Ann Thorac Surg"},{"key":"1462_CR5","first-page":"115","volume":"47","author":"T Yamashiro","year":"2020","unstructured":"Yamashiro T, Hibiya M, Takagi Y. Study on influencing. factors on heparin reactivity. Jpn J Extra-Corpor Technol. 2020;47:115\u201321.","journal-title":"Jpn J Extra-Corpor Technol"},{"key":"1462_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s10047-024-01435-1","author":"T Yamashiro","year":"2024","unstructured":"Yamashiro T, Takami Y, Takagi Y. Contributing factors to heparin resistance during cardiopulmonary bypass. J Artif Organs. 2024. https:\/\/doi.org\/10.1007\/s10047-024-01435-1.","journal-title":"J Artif Organs"},{"key":"1462_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/pharmrev.122.000684","volume":"75","author":"J Hogwood","year":"2023","unstructured":"Hogwood J, Mulloy B, Lever R, Gray E, Page CP. Pharmacology of heparin and related drugs: an update. Pharmacol Rev. 2023;75:328\u201379.","journal-title":"Pharmacol Rev"},{"key":"1462_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1042\/bj1970599","volume":"197","author":"B Casu","year":"1981","unstructured":"Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, et al. The structure of heparin oligosaccharide fragments with high anti-factor Xa activity containing the minimal antithrombin III-binding sequence. chemical and 13C nuclear-magnetic-resonance studies. Biochem J. 1981;197:599\u2013609.","journal-title":"Biochem J"},{"key":"1462_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0006-291X(83)90550-8","volume":"116","author":"J Choay","year":"1983","unstructured":"Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic penta- saccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983;116:492\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1462_CR10","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1016\/S0021-9258(18)90755-6","volume":"259","author":"U Lindahl","year":"1984","unstructured":"Lindahl U, Thunberg L, B\u00e4ckstr\u00f6m G, Riesenfeld J, Nordling K, Bj\u00f6rk I. Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem. 1984;259:12368\u201376.","journal-title":"J Biol Chem"},{"key":"1462_CR11","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1021\/bi00394a024","volume":"26","author":"DH Atha","year":"1987","unstructured":"Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry. 1987;26:6454\u201361.","journal-title":"Biochemistry"},{"key":"1462_CR12","doi-asserted-by":"publisher","first-page":"15467","DOI":"10.1016\/S0021-9258(18)66735-3","volume":"261","author":"A Danielsson","year":"1986","unstructured":"Danielsson A, Raub E, Lindahl U, Bj\u00f6rk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem. 1986;261:15467\u201373.","journal-title":"J Biol Chem"},{"key":"1462_CR13","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0021-9258(18)34900-7","volume":"257","author":"DM Tollefsen","year":"1982","unstructured":"Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem. 1982;257:2162\u20139.","journal-title":"J Biol Chem"},{"key":"1462_CR14","doi-asserted-by":"publisher","first-page":"26950","DOI":"10.1016\/S0021-9258(19)74202-1","volume":"268","author":"ZF Huang","year":"1993","unstructured":"Huang ZF, Wun T-C, Broze GJ. Kinetics of factor Xa inhibition by tissue factor. pathway inhibitor. J Biol Chem. 1993;268:26950\u20135.","journal-title":"J Biol Chem"},{"key":"1462_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11748-023-01936-5","volume":"72","author":"K Ito","year":"2024","unstructured":"Ito K, Sasaki K, Ono M, Saiki Y, et al. Investigation of real-world heparin resistance and anticoagulation management prior to cardiopulmonary bypass: report from a nationwide survey by the Japanese association for thoracic Surgery heparin resistance working group. Gen Thorac Cardiovasc Surg. 2024;72:8\u201314.","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"1462_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12871-019-0846-z","volume":"19","author":"D Dirkmann","year":"2019","unstructured":"Dirkmann D, Nagy E, Britten MW, Peters J. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the hemochron signature elite and the abbott i-STAT: agreement, concordance, and clinical reliability. BMC Anesthesiol. 2019;19:174.","journal-title":"BMC Anesthesiol"},{"key":"1462_CR17","doi-asserted-by":"publisher","first-page":"107602962097549","DOI":"10.1177\/1076029620975494","volume":"26","author":"JE Wehner","year":"2020","unstructured":"Wehner JE, Boehne M, David S, Brand K, Tiede A, Bikker R. Activated clotting time (act) for monitoring of low-dose heparin: performance characteristics in healthy adults and critically ill patients. Clin Appl Thromb Hemost. 2020;26:1076029620975494.","journal-title":"Clin Appl Thromb Hemost"},{"key":"1462_CR18","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1213\/ANE.0000000000003981","volume":"129","author":"RM Sniecinski","year":"2019","unstructured":"Sniecinski RM, Bennett Guerrero E, Shore LL. Anticoagulation. management and heparin resistance during cardiopulmonary bypass: a survey of society of cardiovascular anesthesiologists members. Anesth Analg. 2019;129:e41\u20134.","journal-title":"Anesth Analg"},{"key":"1462_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0049-3848(78)90293-1","volume":"12","author":"GA Mitchell","year":"1978","unstructured":"Mitchell GA, Hudson PM, Huseby RM, Pochron SP, Gargiulo RJ. Fluorescent substrate assay for antithrombin III. Thromb Res. 1978;12:219\u201325.","journal-title":"Thromb Res"},{"key":"1462_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.648","volume":"8","author":"T Miike","year":"2021","unstructured":"Miike T, Sakamoto Y, Inoue S. Influence of high-dose antithrombin on platelet function and blood coagulation. Acute Med Surg. 2021;8: e648.","journal-title":"Acute Med Surg"}],"container-title":["Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10047-024-01462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10047-024-01462-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10047-024-01462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T17:30:05Z","timestamp":1747243805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10047-024-01462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s10047-024-01462-y","relation":{},"ISSN":["1434-7229","1619-0904"],"issn-type":[{"value":"1434-7229","type":"print"},{"value":"1619-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}